This study quantifies CXCR4 expression in early stage disease and evaluates its association with gender-specific recurrence-free (RFS) and overall survival (OS) in resected stage I-III NSCLC patients. The gene discussed is CXCR4; the disease is non-small cell lung carcinoma.